WVE
HealthcareWave Life Sciences Ltd. · Biotechnology · $1B
What is Wave Life Sciences Ltd.?
Wave Life Sciences is a clinical-stage genetic medicine company focused on developing stereopure oligonucleotides for rare and serious diseases. Incorporated in 2012 and headquartered in Singapore, it operates through its proprietary PRISM platform.
Wave Life Sciences designs and develops oligonucleotide therapies that target RNA to reduce harmful proteins or restore functional ones. Its pipeline spans neurological conditions and hepatic diseases, with programs in ALS, Huntington's disease, Duchenne muscular dystrophy, and Alpha-1 antitrypsin deficiency. The company generates revenue primarily through collaboration agreements with partners including Pfizer and Takeda.
Wave Life Sciences was founded in 2015 and is headquartered in Singapore.
- PRISM stereopure oligonucleotide platform
- CNS pipeline: WVE-004 (ALS/FTD) and WVE-003 (Huntington's disease)
- WVE-N531 for Duchenne muscular dystrophy
- GalNAc-conjugated AIMers for hepatic indications including AATD
Is WVE a Good Stock to Buy?
UQS Score rates WVE as Poor overall, reflecting the challenges common to clinical-stage biotech companies.
Growth and Risk both register at a Neutral level, suggesting the pipeline carries some forward potential and that risk is not extreme relative to peers at this stage.
Quality and Moat are both rated Weak, and Valuation is Elevated — a combination that warrants careful consideration for investors evaluating risk-adjusted returns.
See the full pillar breakdown and detailed financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does WVE pay dividends?
No — Wave Life Sciences Ltd. does not currently pay a dividend.
Wave Life Sciences does not pay a dividend. As a clinical-stage company, capital is directed toward research, pipeline development, and collaboration programs rather than shareholder distributions. This is typical for pre-profitability biotech firms.
When does WVE report earnings?
Wave Life Sciences reports earnings on a quarterly cadence, consistent with US-listed equities.
As a clinical-stage company, quarterly results are shaped largely by collaboration revenues and research expenditures rather than product sales. Pipeline milestones and partner updates tend to drive investor attention around each reporting period.
For the most recent quarter's results, visit Wave Life Sciences' investor relations page directly.
WVE Price History
+7.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Wave Life Sciences Ltd.?
Based on Wave Life Sciences Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Wave Life Sciences do?
Wave Life Sciences develops stereopure oligonucleotide therapies for rare genetic diseases. Using its PRISM platform, the company targets RNA to modulate protein expression. Its pipeline includes programs for ALS, Huntington's disease, Duchenne muscular dystrophy, and liver conditions, with collaborations supporting development.
Does WVE pay dividends?
WVE does not currently pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and pipeline advancement. Investors in WVE are generally seeking pipeline-driven value rather than income.
When does WVE report earnings?
Wave Life Sciences follows a standard quarterly reporting schedule. Exact dates vary each period. For upcoming earnings timing, check the company's investor relations page or your brokerage's earnings calendar.
Is WVE a good stock to buy?
UQS Score rates WVE as Poor, with Weak Quality and Moat scores alongside an Elevated Valuation. Neutral Growth and Risk scores offer some balance, but the overall profile reflects the high-uncertainty nature of clinical-stage biotech investing. Pro members can view the complete breakdown.
Is WVE overvalued?
WVE's Valuation pillar is rated Elevated under the UQS framework, suggesting the market may be pricing in significant pipeline success. For clinical-stage companies without product revenue, valuation is inherently speculative and tied to trial outcomes.
What is WVE's market cap bracket?
Wave Life Sciences is classified as a small-cap company. This places it among smaller publicly traded biotechs, where liquidity and volatility can differ meaningfully from large- or mega-cap peers in the healthcare sector.
Is WVE a long-term quality investment?
From a long-term quality standpoint, WVE's Weak Quality and Moat scores indicate limited financial durability and competitive entrenchment at this stage. Long-term outcomes depend heavily on clinical trial results and the ability to advance programs toward commercialization.
Who founded Wave Life Sciences?
Wave Life Sciences was incorporated in 2012 and formally established in 2015. Founding and leadership history is publicly available through the company's official disclosures and investor relations materials.
Unlock Full WVE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar score
- ✓Compare WVE against clinical-stage biotech peers
- ✓Track score changes as pipeline milestones evolve
Pro Analysis
WVE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 23.1 | 2.1 | 17.0 | 55.9 | 48.0 | 0.0 | +2.1 |
| May 8, 2026 | 21.0 | 0.0 | 17.0 | 55.9 | 36.9 | 0.0 | -2.1 |
| May 2, 2026 | 23.1 | 2.1 | 17.0 | 55.9 | 47.9 | 0.0 | -0.1 |
| Apr 2, 2026 | 23.2 | 2.1 | 17.0 | 56.3 | 47.9 | 0.0 | — |
WVE — Pillar Breakdown
Quality
— 2.1/100 (25%)Wave Life Sciences Ltd. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 55.9/100 (20%)Wave Life Sciences Ltd. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 48.0/100 (15%)Wave Life Sciences Ltd. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Wave Life Sciences Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 17/100 (25%)Wave Life Sciences Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for WVE.
Score Composition
Financial Data
More Stock Analysis
How is the WVE UQS Score Calculated?
The UQS (Unified Quality Score) for Wave Life Sciences Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Wave Life Sciences Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Wave Life Sciences Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.